Arrowhead Pharmaceuticals Inc (ARWR) General Counsel Patrick O’brien Sells 72,000 Shares
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) General Counsel Patrick O’brien sold 72,000 shares of the company’s stock in a transaction that occurred on Friday, January 18th. The stock was sold at an average price of $14.43, for a total transaction of $1,038,960.00. Following the transaction, the general counsel now directly owns 233,000 shares of the company’s stock, valued at approximately $3,362,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
ARWR traded down $0.11 during trading on Friday, hitting $14.52. 1,529,987 shares of the company’s stock were exchanged, compared to its average volume of 1,687,221. The company has a quick ratio of 6.37, a current ratio of 6.37 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals Inc has a 1 year low of $4.77 and a 1 year high of $22.39. The company has a market cap of $1.35 billion, a P/E ratio of -22.34 and a beta of 1.96.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, December 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. Arrowhead Pharmaceuticals had a negative net margin of 337.32% and a negative return on equity of 57.18%. The company had revenue of $11.26 million during the quarter, compared to the consensus estimate of $3.73 million. Research analysts anticipate that Arrowhead Pharmaceuticals Inc will post 1.49 earnings per share for the current year.
Several brokerages recently commented on ARWR. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $25.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 4th. Cantor Fitzgerald upped their price target on shares of Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, October 4th. Chardan Capital set a $25.00 price target on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, October 14th. BidaskClub lowered shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Arrowhead Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $21.36.
TRADEMARK VIOLATION NOTICE: This article was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://theolympiareport.com/2019/01/19/arrowhead-pharmaceuticals-inc-arwr-general-counsel-patrick-obrien-sells-72000-shares.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.